Depemokimab
Based on 1 Customer Validation
Depemokimab (GSK-3511294) is a long-acting anti-IL-5 monoclonal antibody. Depemokimab can be used for research of asthma.
For research use only. We do not sell to patients.
- Purity: 95.24%
- CAS No.: 2243274-14-6
- Molecular Weight:145.8 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG1 kappa
Human
IL-5
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized IL-15 Protein, Human can bind Depemokimab. The EC50 for this effect is 96.02 ng/mL.
Chemical Information
-
CAS No. 2243274-14-6
-
Appearance Liquid
-
Molecular Weight 145.8 kDa
-
Color Colorless to light yellow
-
SMILES
[Depemokimab]
-
Synonyms
GSK-3511294
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (256 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Calzetta L, et al. Investigational Treatments in Phase I and II Clinical Trials: A Systematic Review in Asthma. Biomedicines. 2022 Sep 19;10(9):2330. [Content Brief]
[2]. Singh D, et al. A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma. Br J Clin Pharmacol. 2022 Feb;88(2):702-712. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)